The Mounjaro NHS Waiting List: How Long, Who Qualifies, and Your Options

What NICE and NHS England have actually agreed, and why the queue exists

The starting point is NICE Technology Appraisal 1026, published on 23 December 2024 and updated in September 2025. NICE concluded that tirzepatide is cost-effective for NHS use and recommended it for adults with a BMI of 35 or above who also have at least one weight-related comorbidity, conditions such as high blood pressure, type 2 diabetes, obstructive sleep apnoea, dyslipidaemia or cardiovascular disease. NICE's full recommendation (TA1026) sets out the details, including the lower BMI thresholds that apply for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds.

NHS England chose to phase rollout because prescribing demand at full eligibility would outstrip supply. The first cohort, available since June 2025, covers adults with a BMI of 40 or above plus four or more of those five qualifying conditions. A second cohort (BMI 35 to 39.9, still requiring four conditions) was activated in June 2026. A third phase (BMI 40-plus, three conditions) is currently projected for around March 2027. You can read the phased plan in full on NHS England's tirzepatide rollout guidance.

Even meeting the criteria does not guarantee a prescription this week. From April 2026 GP practices may prescribe under the new QOF contract, but participation is optional. Some practices are ready; many are not. Every patient must also enrol in wraparound diet and activity support. The result is a postcode lottery that frustrates a lot of people, and understandably so. If you have been told you qualify but your practice isn't yet offering the service, our guide to getting Mounjaro on the NHS covers the practical steps to push for access.

The trial evidence that makes clinicians confident while patients wait

The queue exists partly because the evidence is strong. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, adults with obesity taking tirzepatide 15mg lost an average of around 20 to 21% of their body weight over 72 weeks alongside lifestyle changes. That figure, from a trial involving over 2,500 participants, is the foundation for NICE's endorsement and the reason demand is running ahead of supply.

SURMOUNT-5, also published in the NEJM, subsequently compared tirzepatide head-to-head with semaglutide 2.4mg (the active ingredient in Wegovy) over 72 weeks in adults with obesity. Tirzepatide produced greater average weight reduction. The headline numbers matter less than what they signal: tirzepatide's dual mechanism, acting on both GIP and GLP-1 receptors rather than one, appears to translate into larger average losses in clinical trials. Our Mounjaro overview explains how that mechanism works in practice.

Results in real life vary. Dose, adherence, diet, activity and individual biology all play a role. A prescriber reviewing your health history can give you a more grounded sense of what to expect than any population average. Framing the trial data as a ceiling rather than a guarantee is something our clinical team considers routine, it's a question they hear most weeks.

Private treatment as an alternative to the NHS waiting list

If you do not yet meet the NHS thresholds, or if your GP practice is not yet set up, a regulated private pharmacy is the legal route to tirzepatide while you wait. The licensed eligibility criteria for private prescribing follow the medicine's SmPC: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. That is considerably broader than the current NHS criteria.

Private treatment has a real cost, and it is worth reading about how Eli Lilly's 2025 UK price increase affected Mounjaro costs before you budget. The key consumer protection question is not which provider is cheapest, but whether the pharmacy is GPhC-registered and whether a qualified prescriber will review your case individually before issuing a prescription. At nume, every consultation is read by a GPhC-registered Independent Prescriber on the day it arrives. That review is personal (not automated) and it considers your full health picture before any treatment is approved.

Anyone offering Mounjaro without a clinical assessment is operating outside the law. The MHRA has warned publicly about counterfeit pens seized from illegal online sellers, some containing dangerous substances. If a price looks far below market, or a seller claims you can obtain treatment without a consultation, treat that as a red flag and report the seller via the Yellow Card scheme. For a clear explanation of how to verify any online pharmacy's registration, see our guide to buying Mounjaro online safely.

What to do if you're on the waiting list and unsure what happens next

First, confirm with your GP practice whether they are participating in the NHS tirzepatide service under the 2026/27 QOF. If they are not, you can ask to be referred to a specialist weight management service that may have access under a separate commissioning route. Our page on Mounjaro through your GP on the NHS covers how those conversations typically go.

If you decide to explore private treatment in the meantime, the process through a regulated pharmacy begins with a free clinical consultation. There is no referral required, and if a prescriber confirms suitability, treatment can begin quickly. The eligibility criteria for NHS versus private routes differ meaningfully, understanding both helps you make an informed decision about which path fits your circumstances.

You are also welcome to check your eligibility with our prescribers at any point. The consultation is free, there is no obligation, and it is a reasonable way to find out where you stand while the NHS queue moves.